Antiviral Drugs Market - By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors), By Indication (Influenza, HIV AIDS, Hepatitis, Coronavirus Infection), By Type, By Age Group & Forecast, 2022-2028

Antiviral Drugs Market - By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors), By Indication (Influenza, HIV AIDS, Hepatitis, Coronavirus Infection), By Type, By Age Group & Forecast, 2022-2028

Antiviral Drugs Market Size

Antiviral Drugs Market size crossed USD 48 billion in 2021 and is expected to progress at 3.4% CAGR through 2028 due to the higher incidence rate of infectious diseases. The growing prevalence of HIV infections across the globe is one of the dominant factors influencing the demand for antiviral drugs.
 

For instance, according to the U.S. Department of Health & Human Services and Minority HIV/AIDS Fund, in 2020, around 37.7 million individuals with HIV infections were reported across the globe. Thus, increasing product accessibility in developed countries for advanced treatments, including antiretroviral therapy, to cater disease burden will propel the overall antiviral drugs market growth.
 

Further, as per the World Health Organization’s data in 2019, over 1.5 million new cases with hepatitis B infection are reported every year and nearly 296 million individuals were estimated to be infected with chronic hepatitis B across the world. Therefore, the rising incidence rate of several other infectious diseases such as herpes simplex virus, hepatitis virus, and influenza will stimulate the market revenue.
    

The COVID-19 pandemic has positively impacted the product sales of antiviral drugs. Sudden spike in the number of COVID-19 cases and primary focus of healthcare facilities on the treatment of COVID-19 patients has stimulated the market growth. Moreover, numerous pharmaceutical companies were focusing on new drug development for effective treatment and better patient outcomes. These companies were also collaborating to cater product demand throughout the period.
 

For instance, in May 2020, Cipla Inc. partnered with Gilead Sciences for manufacturing and distribution of remdesivir to treat COVID-19 patients in more than 127 countries. Therefore, proactive collaborations and strategic efforts by market players to broaden their manufacturing capacities antiviral drugs for catering to a large patient base have fuelled the overall antiviral drugs market share.
 

Antiviral drugs are the class of medicines that are used to treat viral infections such as hepatitis, HIV and influenza among others. These drugs are prescribed in the forms of tablet, liquid, injectable solution and inhaled powders. Antiviral drugs are used to eradicate disease causing viruses from the body. There are certain types of antiviral medications available in the market such as protease inhibitors, reverse transcriptase inhibitors (NRTIs and NNRTIs), neuraminidase inhibitors and DNA polymerase inhibitors.
 

Impact of COVID-19 Pandemic

Robust investment in research and development activities by numerous pharmaceutical organizations will offer enormous growth opportunities to the antiviral drugs business in the forthcoming years. Several key market players are actively involved in development of novel drug therapeutics to treat infectious diseases that will strengthen the market growth potential. Moreover, several national organizations are highly investing in R&D activities to minimize the disease burden.
 

For instance, in 2020, the National Institute of Allergy and Infectious Diseases (NIAID) partnered with NIH Institutes and Centers for intensive research program to prioritize and accelerate the development of COVID-19 therapeutics. Moreover, in 2022, the Antiviral Drug Discovery Centers (AViDD) for Pandemic Pathogens will be established by the NIAID in the U.S.
 

These research facilities will be highly focused on SARS-CoV-2 and various other viruses having pandemic potential such as bunyaviral, paramyxoviruses, togaviruses, picornaviruses and filoviruses, leading to an increase in product launches in the future. Further, some governments as well as other private organizations have implemented awareness programmes regarding availability of advanced therapeutics for sexually transmitted diseases.
 

Antiviral Drugs Market Analysis

Based on drug class, the antiviral drugs market is divided into reverse transcriptase inhibitors, DNA polymerase inhibitors, neuraminidase inhibitors, protease inhibitors, and others. The reverse transcriptase inhibitors segment was accounted for more than USD 11 billion revenue in 2021. Non-nucleoside as well as nucleoside reverse transcriptase inhibitors are used in the treatment of hepatitis and human immunodeficiency virus (HIV) infections. The combination of these drugs is utilized as highly active antiretroviral therapy for HIV infections.
 

Moreover, reverse transcriptase inhibitors are also being commonly used in resource-limited regions with its several advantages such as enhanced bioavailability, higher success rate and affordability with low genetic barriers, thereby stimulating the segmental demand. Thus, with high potential to reduce severity of HIV infections, expanding product availability, and novel product launches, the segment will foresee significant product demand in the forthcoming years.
 

Antiviral drugs market on basis of indication is segmented into coronavirus infection, HIV AIDS, influenza, hepatitis, herpes simplex virus (HSV) and others. Growing incidence rate of infectious viruses such as SARS COV-2, Ebola, swine flu and Zika virus have boosted the demand for effective antiviral drugs therapies. Coronavirus infection segment held more than 17% market share in 2021 and is projected to witness substantial growth rate in near future. Occurrence of COVID-19 pandemic, resulting into sudden surge in the number of cases, globally, has offered unprecedented growth opportunities to the segment.
 

Moreover, strong presence of market players that are focusing on research and development activities and product launches to combat COVID-19 infection is expected to drive the antiviral drugs market growth. For instance, in December 2021, Merck and Ridgeback Biotherapeutics received emergency use authorization for molnupiravir by the U.S. Food and Drug Administration (FDA).
 

The molnupiravir is an investigational oral antiviral drug that is used to treat mild to moderate coronavirus infection in adults. Also, Remdesivir is another clinically proven drug and promising treatment against the COVID-19 infection. Expanded manufacturing and commercialization of these drugs to cater huge patient population across the globe has significantly contributed to the segmental revenue growth. Thus, growing demand for antiviral drug therapy for coronavirus infection will stimulate the overall market forecasts.
 

On basis of type, the antiviral drugs market is segmented into branded and generic. Branded drugs segment is estimated to proceed at 2.9% CAGR through 2028. Considerable segment size is owing to the high adoption of effective branded drugs and broader product availability in the developed markets. Further, the high product prices of such patented medications allow industry players to maximize their product associated revenues.
 

Additionally, increasing research and development activities coupled with speedy product approvals will further accelerate the segment demand. Furthermore, incidence of newly emerging infectious diseases with no prior approved medications leads to high usage of recently launched branded drugs that will fortify the overall market outlookduring the projection period.
 

The antiviral drugs market on basis of age group is segmented into pediatric, adult, and geriatric. Adult segment was valued over USD 16.5 million revenue in 2021. Growing prevalence of several sexually transmitted infectious diseases among adults around the globe will influence the overall market statistics.
 

For instance, as per the World Health Organization, it is estimated that around 491 million people aged 15–49 years were having HSV-2 infection in 2016 that causes genital herpes. The awareness programs and campaigns regarding the available treatment therapies for STDs will further influence the product adoption rate among adults. Thus, growing disease prevalence rate among adult population will stimulate the demand for antiviral drugs over the analysis timeframe.
 

North America antiviral drugs market constituted for over 56% business share in 2021. Ongoing clinical trials and increasing product approvals in the region are the major factors impacting the regional industry expansion. In addition, large population suffering from several infections will contribute to the overall market growth.
 

Moreover, recent coronavirus outbreak has led to increased patient base, thereby impelling the demand for effective antiviral drugs, especially in the U.S. Furthermore, strong presence of industry players in the region that are involved in the development of extensive product portfolio to curb disease burden will boost the regional market share.
 

Antiviral Drugs Market Share

Some of the notable key market players operating in the antiviral drug industry include

• Gilead Sciences
• AbbVie, Inc
• Merck & Co
• GlaxoSmithKline plc
• Aurobindo Pharma Limited
• ohnson & Johnson
• Sun Pharmaceutical Industries Ltd
• Cipla, Inc
• Mylan N V
• Bristol-Myers Squibb

These industry players are adopting several growth strategies to strengthen product offerings and attain sustainable competitive advantage.
 

Some of the recent industry developments

• In January 2022, Aurobindo Pharma Limited launched molnupiravir under the brand name, Molnaflu, for COVID-19 treatment in India. This will strengthen the company’s product portfolio thereby, creating revenue growth opportunities.
   
• In August 2020, Pfizer Inc. announced a multi-year agreement with Gilead Sciences, Inc. to manufacture and supply Gilead’s remdesivir, an investigational antiviral drug used to treat COVID-19 patients. These has broadened the company’s customer reach.
   
• In October 2020, Roche announced partnership with Atea Pharmaceuticals to develop, manufacture, and commercialize Atea’s AT-527, an investigational oral antiviral drug for the COVID-19 treatment. This partnership has enhanced the firm’s development potential, thus strengthening its market position.
   

The antiviral drugs market report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2022 to 2028 for the following segments

Click here to Buy Section of this Report

By Drug Class

• DNA polymerase inhibitors
• Reverse transcriptase inhibitors
• Protease inhibitors
• Neuraminidase inhibitors
• Others

By Indication

• Influenza
• HIV AIDS
• Hepatitis
• Herpes simplex virus (HSV)
• Coronavirus infection
• Others

By Type

• Branded
• Generic

By Age Group

• Adult
• Pediatric
• Geriatric

The above information is provided for the following regions and countries

By Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Poland
  • Switzerland
  • The Netherlands
  • Sweden
  • Others
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Singapore
  • Indonesia
  • Thailand
  • Malaysia
  • Philippines
  • Others
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Others
• Middle East Asia & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Others